Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
Akero Therapeutics (NASDAQ:AKRO), a clinical-stage biotechnology company focused on developing treatments for serious metabolic diseases, has announced its participation in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference.
The presentation is scheduled for September 8, 2025, at 10:45 a.m. E.T. in New York. Investors can access the live webcast through Akero's investor relations website, with an archived replay available after the event.
Akero Therapeutics (NASDAQ:AKRO), società biofarmaceutica in fase clinica specializzata nello sviluppo di terapie per gravi malattie metaboliche, ha annunciato la sua partecipazione al Morgan Stanley 23rd Annual Global Healthcare Conference.
La presentazione si terrà il 8 settembre 2025 alle 10:45 E.T. a New York. Gli investitori potranno seguire la diretta in webcast tramite il sito per gli investitori di Akero; sarà disponibile anche una registrazione archiviata dopo l'evento.
Akero Therapeutics (NASDAQ:AKRO), una compañía biotecnológica en fase clínica centrada en desarrollar tratamientos para graves enfermedades metabólicas, ha anunciado su participación en la Morgan Stanley 23rd Annual Global Healthcare Conference.
La presentación está programada para el 8 de septiembre de 2025 a las 10:45 a.m. E.T. en Nueva York. Los inversores podrán acceder a la transmisión en vivo a través del sitio web de relaciones con inversores de Akero, y habrá una repetición archivada disponible tras el evento.
Akero Therapeutics (NASDAQ:AKRO))는 심각한 대사 질환 치료제 개발에 주력하는 임상 단계의 바이오기업으로, Morgan Stanley 23rd Annual Global Healthcare Conference에 참가한다고 발표했습니다.
발표는 뉴욕 현지 시간 2025년 9월 8일 오전 10:45 E.T.에 예정되어 있습니다. 투자자들은 Akero의 투자자 관계 웹사이트를 통해 생중계 웹캐스트에 접속할 수 있으며, 행사 후에는 녹화 재상영도 제공됩니다.
Akero Therapeutics (NASDAQ:AKRO), une société biotechnologique en phase clinique axée sur le développement de traitements pour des maladies métaboliques graves, a annoncé sa participation à la Morgan Stanley 23rd Annual Global Healthcare Conference.
La présentation est programmée le 8 septembre 2025 à 10h45 E.T. à New York. Les investisseurs pourront accéder au webdiffusion en direct via le site des relations investisseurs d'Akero; une rediffusion archivée sera disponible après l'événement.
Akero Therapeutics (NASDAQ:AKRO), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Therapien für schwere Stoffwechselerkrankungen spezialisiert hat, hat seine Teilnahme an der Morgan Stanley 23rd Annual Global Healthcare Conference angekündigt.
Die Präsentation ist geplant für den 8. September 2025 um 10:45 Uhr E.T. in New York. Investoren können das Live-Webcast über die Investor-Relations-Website von Akero verfolgen; eine archivierte Wiedergabe steht nach der Veranstaltung zur Verfügung.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September 8, 2025, at 10:45 a.m. E.T. in New York, NY.
A live webcast of the Company presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website.
About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Akero’s lead product candidate, efruxifermin (EFX), is currently being evaluated in three ongoing Phase 3 clinical studies: SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, and SYNCHRONY Real-World in patients with MASH or MASLD (metabolic dysfunction associated steatotic liver disease). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. Akero is headquartered in South San Francisco. Visit us at akerotx.com and follow us on LinkedIn and X for more information.
Investor Contact:
Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com
Media Contact:
Peg Rusconi
Deerfield Group
617.910.6217
peg.rusconi@deerfieldgroup.com
FAQ
When is Akero Therapeutics (AKRO) presenting at the Morgan Stanley Healthcare Conference 2025?
How can investors watch Akero Therapeutics' Morgan Stanley conference presentation?
What type of company is Akero Therapeutics (AKRO)?
Where will the Morgan Stanley Healthcare Conference 2025 with Akero Therapeutics be held?
